• Unmet Need

TRODELVY

Unmet Need

INTERNATIONAL GUIDELINES RECOMMEND TRODELVY AS THE CATEGORY 1 / PREFERRED REGIMEN IN 2L mTNBC1,2

SYSTEMIC THERAPY FOR RECURRENT UNRESECTABLE (LOCAL OR REGIONAL) OR STAGE IV (M1) DISEASE

Adapted from NCCN Guidelines Version 2. 2026 Invasive Breast Cancer.


  1. For treatment of brain metastases, see NCCN Guidelines for Central Nervous System Cancers.
  2. Assess for germline BRCA1/2 PVs in all patients with recurrent or metastatic breast cancer to identify candidates for PARPi therapy.
  3. Principles of HER2 Testing (BINV-A). The distinction between HER2 (ERBB) test results of IHC 0/absent membrane staining, IHC 0+/with membrane staining (faint, partial membrane staining in ≤10%), IHC 1+, or 2+/ISH negative is currently clinically relevant for therapy selection.
  4. Sacituzumab govitecan-hziy may be considered for later line if not used as second line therapy.
  5. Fam-trastuzumab deruxtecan may be considered in a later line for HER2 (ERBB) IHC 1+ or 2+/ISH negative, if not used in second line or may be considered first line therapy when disease has progressed during or within 6 months after completing adjuvant chemotherapy. Fam-trastuzumab deruxtecan-nxki is associated with ILD/pneumonitis. Regular monitoring for this serious side effect is recommended. For patients with a history of ILD/pneumonitis, there are no data on managing safety or toxicity of this drug in a trial.
PATIENTS WITH mTNBC

Adapted from ESMO Metastatic Breast Cancer Living Guideline v1.2 April 2025.


mTNBC remains the most difficult-to-treat breast cancer subtype4

Patients with mTNBC are lost with each line of treatment5

For patients with mTNBC, survival and quality of life are the two most important aspects of treatment6

There is a significant need for more efficacious and tolerable treatment options in mTNBC7

ABBREVIATIONS:

1L, first line; 2L, second line; 3L, third line; 4L, fourth line; ESMO, European Society for Medical Oncology; mTNBC, metastatic triple-negative breast cancer; TNBC, triple-negative breast cancer; CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mut, mutant; OS, overall survival; ChT, chemotherapy; ESCAT, ICI, immune checkpoint inhibitor; ESMO Scale for Clinical Actionability of molecular Targets; MCBS, ESMO-Magnitude of Clinical Benefit Scale; mTNBC, metastatic triple-negative breast cancer; mut, mutation; wt, wild-type.
(α)ESCAT scores apply to genomic alterations only.

REFERENCES:

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 2. 2026 – February 27, 2026. Invasive Breast Cancer. 2. ESMO Metastatic Breast Cancer Living Guideline v1.2 April 2025 3. Fangyuan, et al. Oncotarget. 2017;8(42):73329–73344. 4. Seah DS, et al. J Natl Compr Canc Netw. 2014;12(1):71–80. 5. Kantar Health CancerMPact. Accessed: March 2021. 6. Canadian Agency for Drugs and Technologies (CADTH). Available at: https://www.cadth.ca/sites/default/files/attachments/2021-08/Sacituzumab%20govitecan%20 -%20Patient%20Group%20Input%20-%20For%20posting.pdf. Accessed: April 2022. 7. Lehmann BD, et al. J Clin Invest. 2011;121(7):2750–2767. 8. Abramson VG, et al. Cancer. 2015;121(1):8–16. 9. O’Reilly D, et al. World J Clin Oncol. 2021;12(3):164–182.